To understand if the DCP1A promoter contributed to ERBB2 degradation through mRNA decapping upon the introduction of the engineered destabilizing 3’UTR ARE of ERBB2 into the breast and lung cancer cells, we performed qRT-PCR and showed that DCP1A promoter expression did not change upon destabilization of the ERBB2 transcript compared to the controls (Figure 4A). The gene discussed is DCP1A; the disease is lung carcinoma.